The Biggest Digital Health Funding Rounds of 2026 So Far

Digital health funding hit $4 billion in the first quarter of 2026. The strongest start since the pandemic peak, with the average deal size at its highest point since late 2021.

But the headline number hides the real story. Nearly 60% of that capital went to about a dozen companies. Eight new unicorns were minted in a single quarter. And one $32 billion plan to merge five companies into an AI health giant collapsed over debt and governance.

The market is not generous right now. It is decisive. These are the rounds that defined the first half of 2026, and what each one tells you.

1. Isomorphic Labs: $2.1 billion to solve all disease

The DeepMind spinout led by Nobel laureate Demis Hassabis raised the largest AI drug discovery round ever, backed by Thrive Capital, Alphabet and sovereign wealth funds. I wrote about why the money is the least interesting part.

Why it matters: The real prize was not the capital. It was locked-up pharma data access nobody else can get.

2. Commure: $750 million at a $7 billion valuation

General Catalyst led the round into the AI back office running inside 130+ health systems. My full breakdown of the Boring Moat thesis is here.

Why it matters: A trillion dollars of admin waste is the biggest honeypot in American healthcare.

3. Whoop: $575 million at a $10.1 billion valuation

The wearable maker raised a Series G on roughly $1.1 billion in annual recurring revenue, nearly tripling its previous valuation, and is reportedly eyeing an IPO.

Why it matters: Consumer health hardware was supposed to be a graveyard. Whoop proved subscriptions change the math.

4. OpenEvidence: $250 million, third round in under a year

The AI medical search engine crossed $100 million in revenue and 40% physician penetration before most companies finish a Series A cycle.

Why it matters: Investors are not paying for potential anymore. They are paying for adoption curves that look vertical.

5. Trase: a $107 million seed round

ARCH Venture Partners led one of the largest seeds in healthtech history for agentic AI in high-stakes operations. Its early work with Duke's cardiology division automated more than 5,000 faxes a month.

Why it matters: When a seed round is nine figures, the market is telling you which category it believes is next.

6. Latent: $80 million for a legal deadline

US insurers must make prior authorization fully electronic by January 2027. Latent's Series A is a direct bet on that regulation, alongside Adonis raising $40 million for the broader revenue cycle.

Why it matters: Compliance deadlines are the most reliable demand signal in healthcare. This one has a date on it.

7. Sage: $65 million for the aging curve

Goldman Sachs Growth Equity led the Series C into AI-powered senior care insights. Every demographic chart in the developed world points the same direction.

Why it matters: Senior care is not a niche. It is the default future of every health system's patient mix.

8. Cala Health: $50 million for wearable therapy

Cala's wrist-worn device treats tremor with targeted stimulation instead of drugs. Therapy delivered as hardware, prescribed like medicine.

Why it matters: Wearables spent a decade measuring disease. The next decade is about treating it.

What the quarter actually taught us

Look at the list again. An AI drug lab, two back-office automators, a subscription wearable, an evidence engine, a regulation play, senior care and wearable therapeutics.

Not one general-purpose AI platform. Not one thin app. Capital is concentrating on companies with proprietary data, owned workflows and revenue that renews itself. The have-nots are learning that a pitch deck full of AI buzzwords no longer clears the bar.

Which round would you have joined? Subscribe free to The HealthTech Signal for the next quarter's breakdown the week it lands.